Results 131 to 134 of about 40,707 (134)

Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab

Proceedings of the National Academy of Sciences of the United States of America, 2017
Qingrong Yan, Alan Korman Korman, Sarah Garrett   +2 more
exaly  

Selective activation of IFNγ–ipilimumab enhances the therapeutic effect and safety of ipilimumab

International Journal of Biological Macromolecules
Kai-Wen Ho, Bo-Cheng Huang
exaly  

Data support longer recurrence‐free survival with nivolumab than with ipilimumab for stage III or IV melanoma

Ca-A Cancer Journal for Clinicians
exaly  

Patterns of onset and resolution of immune‐related adverse events of special interest with ipilimumab

Cancer, 2013
exaly